Table 2 Characteristics of studies involved in chemotherapy of PT treatment
Author | Year | Countr | Follow-Up | Chemo regime | No. chemoth | Surgery Type(%) | Age | Tumor Size (cm) | Histological Type(%) | Margin | LR | DFS | OS | MS | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BCS | M | Be | Bo | M | < 1 cm (%) (positive) | > 1 cm (%) (negative) | ||||||||||||
Chaney, | 2000 | USA | 47 m | doxorubicin- ifosfamide ifosfamide 4300 mg | 4 | 47 | 53 | 41(median) | 4 | / | 20 | 80 | (1) | (99) | 0 | 0 | 4 | 4 |
Guillot, | 2011 | France | 12.65 m | Adriamycin 100 mg *6 | 9 | 97 | 3 | 44(median) | 3 | / | / | 100 | 28 | 72 | 2 | 6 | 6 | 2 |
Morales | 2007 | Mexico | 15 m | Doxorubicin + dacarbazine | 17 | 23.5 | 76.5 | 42(median) | 13 | / | / | 100 | (24) | (76) | 6 | / | 14 | 10 |
Wang, F. | 2014 | China | NA | NA | 8 | 61.4 | 38.6 | 49(mean) | 5 | / | / | 100 | NA | NA | / | 5 | 6 | / |